Percutaneous Transluminal In Vivo Gene
Transfer by Recombinant Adenovirus Background Gene therapy has been proposed as a possible solution to the problem of restenosis after coronary angioplasty. The current study was undertaken to assess conventional methods of gene transfer and to develop percutaneous techniques for introducing genes directly into the coronary arteries of large mammals. Since the anticipated targets of gene therapy against restenosis include atherosclerotic and previously instrumented arteries, we also evaluated gene transfer in atherosclerotic coronary arteries and in two porcine models of restenosis: one using intracoronary stents and a second using balloon overstretch angioplasty.
Methods and Results The conventional method of using perforated balloon catheters to deliver Lipofectin-DNA complexes directly into the coronary arteries of intact animals was applied to 18 porcine coronary arteries including normal arteries, hypercholesterolemic arteries, and those simulating restenosis. The results of this study were consistent with previously published results indicating that only low levels of luciferase gene expression could be obtained by Lipofectinmediated gene transfer. We therefore undertook a second, parallel study to evaluate percutaneous transluminal in vivo gene transfer using a replication-deficient adenoviral vector. A comparison of the two studies revealed that the mean level of reporter gene expression in the cohort undergoing adenoviral infection was 100-fold higher than in the cohort undergoing Lipofection. Analysis of luciferase activity over time in normal arteries revealed that recombinant gene expression was half-T nhe long-term efficacy of coronary angioplasty is limited by the phenomenon of restenosis, attributed primarily to vascular smooth muscle cell (VSMC) migration and proliferation.1,2 Restenosis may be particularly amenable to gene therapy since (1) genes can be transferred directly into coronary arteries, (2) a number of proteins have been shown to inhibit maximal after 1 day, peaked within 1 week, was still halfmaximal at 2 weeks, and declined to low levels by 4 weeks. Histochemical analysis of coronary arteries treated with a second adenovirus expressing a nuclear-localized 83-galactosidase gene demonstrated gene transfer to a limited number of cells in the media and adventitia. Immunohistochemical analysis of Ad5-infused arteries using a monoclonal antibody directed against CD44 identified a periadventitial infiltrate composed of leukocytes.
Conclusions The recombinant adenoviral vectors proved to be far more effective than Lipofectin at delivering foreign genes directly into the coronary arteries of living mammals. Furthermore, the influences of hypercholesterolemia and arterial injury appeared to have little effect on the levels of gene expression obtained using either method. The results demonstrate that low-level recombinant gene expression, the major obstacle impeding gene therapy for the prevention of restenosis, can potentially be overcome by using adenoviral vectors to mediate coronary gene transfer in vivo. The duration of gene expression provided by these vectors and their effective deployment in atherosclerotic, balloon-overstretched, and stented coronary arteries suggest that recombinant adenovirus may have potential for evaluating gene therapy in the clinically informative porcine models of coronary restenosis. (Circulation. 1994; 90:2402 -2413 Key Words * atherosclerosis * restenosis * genes . adenovirus VSMC proliferation, and (3) even a temporary inhibition of VSMC proliferation might be sufficient to limit the formation of restenotic lesions. Direct in vivo gene transfer into peripheral arteries has been demonstrated using Lipofectin or retroviral vectors,3 and canine coronary arteries have been targeted with Lipofectin. 45 However, the low efficiencies inherent in both methods of gene transfer limit the potential for clinical application. Consequently, more efficient techniques of gene transfer must be implemented that are applicable not only to normal coronary arteries but also to atherosclerotic vessels, particularly those displaying the histopathology of restenosis. These considerations, along with studies using replication-deficient adenoviral (Ad5) vectors to mediate in vivo gene transfer into bronchial epithelium6 and other tissues,7 led us to assess the potential of adenoviral vectors for delivering genes directly into four types of porcine coronary vessels: (1) normal coronaries, (2) atherosclerotic coronaries, (3) atherosclerotic coronaries subjected to balloon overstretch injury, and (4) atherosclerotic coronaries subjected to the deployment of intracoronary stents. The last two groups of vessels displayed vigorous VSMC migration and proliferation and serve as models in which to evaluate therapies directed against coronary restenosis.8-'0
The lacZ reporter gene has been used in direct gene transfer experiments targeting peripheral arteries,3'4""1,12 but endogenous ,-galactosidase activity has been observed in arterial sections by our laboratory and others.41' We therefore used the luciferase reporter system13 to accurately quantitate levels of recombinant protein produced in coronary arteries after direct gene transfer. Early experiments used complexes of Lipofectin and a reporter plasmid (pRSVL) in which the long-terminal repeat of the Rous sarcoma virus promoted the transcription of firefly luciferase cDNA. However, the subphysiological levels of recombinant gene expression resulting from Lipofection led us to construct and evaluate a replication-deficient Ad5 vector carrying an analogous expression cassette. Efficient gene transfer using recombinant Ad5 vectors has been demonstrated recently in uninjured peripheral vessels using the method of arterial ligation.12 In addition, percutaneous transluminal delivery of Ad5 vectors to the coronary arteries of rabbits14 and swine15 have been reported; however, this study is the first to demonstrate percutaneous Ad5-mediated gene transfer into atherosclerotic and restenotic coronary arteries of a large animal with relevance to human coronary disease. To characterize the distribution of Ad5-mediated gene transfer in the coronary vasculature after percutaneous delivery by perforated balloon catheters, a second reporter virus expressing a nuclear-localized p-galactosidase gene was constructed and deployed according to the same catheterization protocol. This reporter virus provides for unambiguous identification of transfected cells since the nuclear localization of the blue histochemical reaction product is easily distinguished from the cytoplasmic staining characteristic of both the wildtype Escherichia coli f3-galactosidase and the endogenous mammalian 18-galactosidase activities.4,1
Methods

Porcine Models of Atherosclerosis and Restenosis
Male Hanford miniature swine weighing 50 to 100 lb at exsanguination were used in a protocol adhering to National Institutes of Health and institutional guidelines. The normal cohort of swine received standard feed and was not instrumented before gene transfer. The atherosclerosis and restenosis cohort (8 animals total) was fed a diet of 2% cholesterol, 15% fat, and 1.5% sodium cholate initiated 1 month before the first catheterization. This diet produces marked hypercholesterolemia and coronary atherosclerosis in swine.16 The methods for inducing coronary lesions simulating human restenosis have been described previously.8-10 Briefly, the animals were sedated (IM: ketamine, 20 to 30 mg/kg; acepromazine, 0.22 mg/kg; and atropine, 0.05 mg/kg), intubated, and anesthetized with 2% halothane. A femoral artery was isolated, and a coronary guiding catheter was inserted then directed to the target coronary artery. In one major coronary, a balloonexpandable flexible tantalum stent (oversized by 1.1 to 1.3 times the vessel diameter) was deployed under angiographic guidance. In another major coronary, balloon overstretch injury was imposed with a balloon catheter oversized by 1.1 to 1.3 times vessel diameter by inflating three times for 60 seconds at 8 atm. During each instrumentation, cineangiography was performed to ensure future identification of the target segment. The third major coronary was not instrumented and served as an uninjured atherosclerotic control. After the procedure, the animals were maintained on the atherogenic diet for 1 additional month until gene transfer.
Plasmid and Adenoviral Vectors
For Lipofection of each coronary, 50 ,ug of pRSVL DNA was complexed with 150 ,ug of Lipofectin (BRL) and diluted to a final volume of 4 mL with OptiMEM-I (BRL). The plasmid pRSVL (kindly provided by S. Subramani) carries the longterminal repeat of the Rous sarcoma virus, the firefly luciferase cDNA, the Simian virus 40 (SV 40) small-t intron, and SV 40 polyadenylation signal. '3 The reporter viruses were derived using the replicationdeficient adenovirus type 5 (AdS) cloning system developed and generously provided by F.L. Graham.'7 Briefly, a firefly luciferase expression cassette containing the long-terminal repeat of the Rous sarcoma virus, the firefly luciferase cDNA, the SV 40 small-t intron, and SV 40 polyadenylation signal was subcloned between left-end adenoviral sequences in pXCJL.1 (F.L. Graham, unpublished) to create pXCJL.1/RSV/GL2. This construction was cotransfected into the 293 embryonic kidney cell line with a plasmid (pJM17) that carries a circularized d1309 adenoviral genome'7 to generate a replicationdeficient virus with a substitution of the luciferase expression cassette for the AdS El genes (Fig 1) . Putative viral clones were plaque purified, screened for luciferase insert, propagated, isolated, and titered according to the protocols of Graham (Fig 3) , each of the three major coronary arteries in 8 normal swine were subjected to the same dilatation-infusion procedure, and the swine were similarly euthanized for luciferase determination 1, 7, 14, and 28 days after gene transfer. Luciferase activity cannot be detected in coronary arteries infused with vehicle (OptiMEM-I) alone, and six such negative control arteries were used to establish the day 0 time point. After exsanguination, the hearts were removed to ice-cold phosphate-buffered saline (PBS), coronary arteries were dissected from the myocardium, and all tissue external to the adventitia was carefully removed.
The vessels for luciferase assay were divided into multiple segments (each < Background values from vehicle-infused arteries (equivalent to background from lysis reagent) were subtracted, and relative light units were converted to mass units (picograms) using calibration curves generated from parallel reactions performed with certified luciferase control standard (ALL). The specific activity of the luciferase standard was 16 322 relative light units per picogram; calibration curves were linear over a thousandfold range of luciferase from 10 fg to 10 pg. The coefficient of variation between duplicate samples was typically <5%, and occasional samples with a CV > 10% were subjected to repeat analysis. Values were reported as total mass of active luciferase recovered from each artery. Statistical comparisons were performed by ANOVA using EXCEL 4.0 (Microsoft Corp), with P<.05 considered significant.
Assays for f-Galactosidase Expression
For the characterization of lacZ expression after Ad5-mediated gene transfer, of CsCl-banded Ad5/CMV/nls-LacZ (2x 1010 pfu) was diluted to a final volume of 4 mL with OptiMEM-I and deployed in normal porcine coronary arteries as described above. Three days after gene transfer, the animals were exsanguinated under deep anesthesia, and the target coronary arteries were dissected from the heart complete with subjacent myocardium. The entire length of each major artery was then cross-sectioned into multiple segments, each 3 mm in length, and alternating segments were subjected to quantitative or histochemical assays for 83-galactosidase activity. This exhaustive sampling method made no assumptions concerning the position of the infusion balloon catheter and ensured that the central infusion site was represented by at least one quantitative sample and one histological sample. For the quantitative assay, all tissue external to the adventitia was carefully removed, and the core arterial segment was homogenized in Galacto-Light lysis solution (Tropix Inc). 1B-Galactosidase activity was then determined according to the manufacturer's protocol using a chemiluminescent assay (GalactoLight, Tropix, Inc) and a Monolight 2010 luminometer (ALL). The assay background determined with lysis solution was subtracted, and relative light units were converted to mass units (picograms) using calibration curves generated from parallel reactions performed with purified 13-galactosidase (Sigma Chemical Co). The specific activity of the ,3-galactosidase standard was 760 units per milligram of protein using o-nitrophenyl-13-D-galactopyranoside as a substrate, and the calibration curve was linear over a hundredfold range of ,3-galactosidase from 5 to 500 pg. To control for endogenous ,8-galactosidase activity, three coronary arteries were similarly treated with vehicle (OptiMEM-I) and assayed 3 days after the dilatation-infusion procedure.
For the histological analysis of lacZ expression, the 3-mmlong arterial segments were embedded in tissue-freezing medium (Triangle Biomedical Sciences) and snap-frozen in isopentane cooled with liquid nitrogen for cryosectioning. Four ,um arterial cross sections were collected on Probe-On Plus slides (Fisher Scientific Co), fixed for 10 minutes at 4°C in 2% paraformaldehyde/0.2% glutaraldehyde, and stained for 6 hours in X-gal chromagen as described. 24 The sections were then rinsed in PBS and counterstained with nuclear fast red. Each 3-mm arterial segment of interest was sampled throughout its entire length by collecting cross sections at 0.1-mm intervals and staining with X-gal according to the same protocol.
Immunohistochemistry
The same 3-mm-long arterial segments that demonstrated lacZ expression were examined for the presence of the CD44 antigen. Sections were collected as above, fixed for 10 minutes at 4°C in 1.25% glutaraldehyde, rinsed in PBS, and incubated for 6 hours at room temperature with a monoclonal antibody (BAT31A) specific for porcine CD44 (kindly provided by W.C. Davis, Washington State University, Pullman, Wash). Primary antibody binding was visualized with a Vectastain ABC Kit (Vector Laboratories, Inc), which included a biotinylated secondary antibody raised against mouse IgG and a preformed avidin-biotin complex with horseradish peroxidase as the reporter enzyme. The 3,3'-diaminobenzidine chromagen was deposited at antigenic sites to yield a brown reaction product before counterstaining with hematoxylin.
Results
Luciferase Expression in Normal Porcine Coronary Arteries
The amounts of active luciferase recovered from each normal coronary artery 3 days after the dilatationinfusion procedure are summarized by the first two columns in Fig 2. As indicated by the standard deviations, variability in the levels of gene expression was observed using either Lipofectin-or adenovirus-mediated gene transfer. In normal porcine coronary arteries, the mean luciferase level obtained with the Ad5 vector (range, 11 to 68 pg) was more than two orders of magnitude higher than that obtained with Lipofectin (range, 0.02 to 0.28 pg), a difference that was strongly significant (P=.011). For a given gene transfer method, no significant differences were found in the levels of luciferase recovered from the right coronary, left anterior descending, and circumflex arteries, demonstrating that each of the three major porcine coronary arteries are suitable candidates for gene transfer.
The injury imposed by the 8-atm dilatation-infusion procedure with the oversized perforated balloon catheters was variable, ranging from mild injury consisting of endothelial denudation with medial disorganization to more severe injury in the form of intramedial coronary dissection. This pattern of arterial injury is consistent with that observed after dilatation of porcine coronary arteries using comparably oversized conventional angioplasty balloons in the balloon injury model of coronary restenosis. 10 The axial distribution of gene expression within the coronary arteries was determined by the design of the Wolinsky Infusion Catheter. The balloon is 2 cm in length, with 28 microscopic holes evenly arrayed on the balloon within a central 1.2-cm region. Upon inflation, the infusate is concentrated over the 2-cm length of the balloon, but it is immediately diluted upon encountering blood at either end. Thus, in intact coronary arteries, the vast majority of measurable luciferase activity was focused within a 2-cm segment. This was strictly the case with Lipofectin-mediated gene transfer; however, the high levels of gene expression provided by the adenoviral vector made it possible to detect low levels of luciferase activity in adjoining arterial segments and myocardium.
In strongly positive, AdS -infused coronary arteries containing >10 pg of luciferase, minor amounts of luciferase (less than 1/100th of the total found in the target segment) could be detected in the coronary arteries just proximal and distal to the 2-cm target segments. In these same cases, it was possible to detect minor amounts of luciferase in the epicardium immediately subjacent to the target segment. However, it should be noted that considerable levels of luciferase activity (comparable to that isolated from the coronary artery) could be isolated from the subjacent myocardium when the recombinant adenovirus was delivered in conjunction with coronary dissection that extended to the adventitia. In the typical case where the structural integrity of the coronary artery was maintained, repeated analysis of transmural myocardial samples (right and left atria, apex, septum, anterior, lateral, posterior, and inferior walls) and other major tissues (blood, liver, lung, spleen, aorta, pancreas, kidney, skeletal muscle, and skin) failed to detect any evidence of luciferase activity. This The pathological arterial segments were dilated with perforated balloon catheters during the dilatation-infusion procedure to assess gene transfer under conditions that simulated common interventional targets: atherosclerotic coronaries, previously ballooned atherosclerotic arteries, and atherosclerotic arteries containing intracoronary stents. When removed for determination of luciferase activity 3 days after this procedure, the atherosclerotic arteries displayed variable acute pathology ranging from mild injury consisting of endothelial denudation with medial disorganization to more severe injury in the form of intramedial coronary dissection. The coronary arteries from the balloon-overstretch cohort displayed a similar range of acute pathology, but this was superimposed on the neointimal thickening resulting from the arterial injury imposed 1 month earlier. The arteries from the stented cohort displayed consistent neointimal thickening, but the acute injury was less variable and less pronounced, with no gross evidence of coronary dissection. We hypothesize that the mechanical support provided by the metallic coils embedded within these arteries may have served to prevent coronary dissection during the second procedure.
Time Course of Gene Expression
To further characterize the suitability of adenoviral vectors for delivering gene therapy against restenosis, we determined the time course of recombinant gene expression directed by Ad!/RSV/GL2 in porcine coronary arteries. In addition to the six vehicle-infused arteries used to establish t=0, five time points were studied with 1, 3, 7, 14, and 28 days elapsing between gene transfer and luciferase determination. For each time point, six arteries where subjected to Ad5-mediated gene transfer using the dilatation-infusion protocol as described above. The mean levels of luciferase isolated per coronary artery (picograms per artery) were 14.2 at 1 day, 26.7 at 3 days, 21.7 at 7 days, 12.4 at 14 days, and 0.35 at 28 days. These results are graphically illustrated in Fig 3 along with the standard errors of the means. Substantial variability in luciferase levels was evident at each time point; however, luciferase activity was readily detected in 29 of the 30 Ad5 -infused arteries represented in Fig 3. The one experimental coronary artery in which the luciferase activity was less than twice that of the assay background was obtained at the 28 cient Ad5 vector was deployed into three normal coronary arteries of Hanford miniature swine using Wolinsky Infusion Catheters and the same dilatation-infusion protocol described above. Control arteries in one additional animal were similarly infused with OptiMEM-I vehicle or subjected to injury using conventional angioplasty balloons. The animals were exsanguinated 3 days after instrumentation, and the coronary arteries were subjected to quantitative and histochemical assays for /3-galactosidase activity (Fig 4) . (10.6 pmol of reporter gene) produced a mean of 0.169 pg of luciferase per coronary artery; whereas 4 x 109 adenoviral particles (6.64 fmol of reporter gene) produced a mean of 17.8 pg of luciferase per artery. Accordingly, when compared on a molar basis, the adenovirus is nearly 170 000 times more efficient than Lipofectin at programming recombinant gene expression in porcine coronary arteries. This differential is largely due to the molecular mechanisms by which adenovirus mediates endocytosis, endosomal disruption, and nuclear entry. 26 In contrast, Lipofectin-DNA complexes are effective at penetrating the plasma membrane, but the majority of this DNA is lost, presumably to lysosomal degradation.27 It should be noted that the production of recombinant protein may be influenced by a number of variables besides the frequency of gene transfer, such as (1) promoter strength, (2) promoter attenuation, (3) message stability, (4) translational efficiency, (5) protein stability, (6) nuclear retention of the intact gene, and (7) immunologic interdiction. These variables have been controlled to the greatest extent possible in the current study; however, it is possible that the two methods of gene transfer might differ with respect to nuclear retention and immunologic interdiction.
Variability in the levels of recombinant gene expression after direct in vivo gene transfer poses a significant challenge to this and other potential applications of somatic cell gene therapy. Experiments using Ad5/RSV/ GL2 to mediate high-efficiency gene transfer into cultured adult cardiomyocytes have yielded very consistent results. 28 We therefore attribute a portion of the variability observed in vivo to the formidable task of performing transcatheter delivery in a reproducible fashion. It is likely that interanimal differences including heredity, age, and immunologic responsiveness as well as interarterial differences including vasoconstrictive state, arterial diameter, tortuousity, branching, tapering, and pathology all contributed to variability in the results. In the hypercholesterolemic vessels, increased variability would be consistent with the additional levels of complexity imposed by atherosclerosis, balloon injury, and stent deployment. Nevertheless, the standard deviations of the means from the atherosclerotic and previously injured arteries were similar to those from normal arteries. The number of arteries examined and the variability in luciferase levels make it impossible to exclude the possibility of type 2 error, but Fig 2 clearly demonstrates that the level of luciferase produced by the replication-deficient AdS vector in normal coronary arteries was comparable to that produced in atherosclerotic arteries, including those subjected to balloon overstretch and stent deployment.
The persistence of gene expression in coronary arteries after adenoviral infection is of critical importance in assessing its possible application for gene therapy against restenosis. It is widely held that the late loss of luminal diameter originally gained by balloon angioplasty is largely determined by the healing response that occurs during the days after the intervention and by the migration and proliferation of VSMCs, which subsides within 2 weeks after arterial injury in animal models.29 '30 by guest on December 16, 2017 http://circ.ahajournals.org/
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Hypotheses that consider restenosis as a form of wound healing2 or accelerated atherosclerosis31 would predict that the time course of recombinant gene expression provided by adenoviral vectors (Fig 3) is well suited for gene therapy against restenosis, since maximal therapeutic gene expression can be focused on the critical first 2 weeks after coronary angioplasty. This temporal pattern of gene expression is particularly appropriate for antiproliferative strategies because it effectively covers the period of maximal growth factor stimulation2 and proto-oncogene activation.32 Alternative strategies, such as those directed against extracellular matrix production, may benefit from more extended periods of therapeutic gene expression.
The major obstacle to implementing somatic gene therapy in general (and against restenosis in particular) has been the meager levels of recombinant protein produced by conventional methods of gene transfer. Although Ad5/RSV/GL2 directed levels of luciferase expression 100-fold higher than Lipofectin, the absolute level of recombinant protein per target segment (17.8 pg) was still relatively low due to the short half-life of firefly luciferase in mammalian cells (t1/2 .3 hours).33
The rapid turnover of luciferase protein ensures that the time course of gene expression in porcine coronary arteries (Fig 3) is not complicated by protein accumulation; however, the complementary disadvantage is that luciferase production underestimates the amount of more stable protein that might be produced. For example, the mean level of nuclear-localized 83-galactosidase produced after direct transfer of Ad5/CMV/nlsLacZ into porcine coronary arteries was nearly 10 000-fold higher at 170 ng per artery. In this study, the differences in the promoters used to transcribe each of the two reporter genes (RSV LTR for luciferase versus CMV IE promoter for the nuclear-localized lacZ gene) and in the administered dose (4 x0l pfu for luciferase versus 2x 1010 pfu for lacZ) preclude direct comparison between the two reporter systems. Nevertheless, it is reasonable to suggest that the relative stability of nuclear-localized /-galactosidase in mammalian cells19 contributed to the remarkable difference that we observed in the levels of recombinant protein production.
The expression levels necessary to implement effective gene therapy will vary widely, depending on the nature of the particular molecular strategy; nevertheless, the local concentrations of recombinant protein obtained in this study might well be relevant to the process of restenosis when one considers that many peptide hormones,34 growth factors,35 and cytokines36 are effective at concentrations from 10-1°to 10`1 mol/L. Given that a mean 170 ng of recombinant 18-galactosidase was isolated from arterial segments weighing an average of 0.20 g, we can estimate that the amount of recombinant protein produced was 850 ng per gram of vascular tissue and that mean local concentrations of approximately 7x 10-9 mol/L were attained in this study. Although a direct comparison is not possible, one might note that the daily dose of parenterally administered recombinant interferon-y necessary to inhibit VSMC proliferation after arterial injury in the rat carotid model was only 100 ng per gram of body weight. 37 Microscopic analysis of AdS -infected arterial cross sections stained for l3-galactosidase activity revealed that~'0.13% of the VSMCs in the media and~'1.3% of the cells in the adventitia showed evidence of recombinant gene expression. The frequency of AdS-mediated gene transfer after delivery by perforated balloon catheter was thus fairly low; nevertheless, these results represent a significant improvement over those possible with Lipofectin-DNA complexes. In our experience, the efficiency of gene transfer provided by Lipofectin is so low that it is difficult to distinguish the resulting recombinant ,B-galactosidase above the background of endogenous activity. This problem was overcome in the current study by constructing an efficient Ad5 vector encoding a nuclear-localized 8f-galactosidase. The local delivery of this Ad5 reporter virus to porcine coronary arteries by Wolinsky Infusion Catheters resulted in more positive cells in the adventitia than in the media. Furthermore, the clustering of the positive cells in the adventitia (Fig 4F) suggested distribution by the vasa vasorum. Gene transfer to the vasa vasorum of the adventitia has recently been observed after the administration of AdS vectors to sheep carotid arteries,38 and the vasa vasorum may therefore represent an important pathway by which relatively large (65 to 80 nm) adenoviral particles can gain access to deeper regions of the arterial wall.
The lacZ-positive cells in our study were occasionally associated with regions of vascular damage and often associated with regions of leukocytic infiltration. Our laboratory and others have noted the presence of leukocytes in the luminal thrombi that result from coronary injury in swine.25,39 However, the periadventitial location and proximity of leukocytes to the blue nuclei in Fig 4F suggested the possibility of an inflammatory response involving leukocyte-mediated cytolysis. Immunohistochemistry using an antibody directed against porcine CD44 confirmed that the cellular infiltrate observed in the AdS-infected arteries is composed primarily of leukocytes (Fig 5A) . Leukocytic (Fig 3) . Leuko 
